

Biographical sketch CIRO ISIDORO



Name CIRO ISIDORO

Email ciro.isidoro@med.uniupo.it

Full Professor of General Pathology and Clinical Pathology

Qualified Full Professor of Clinical Biochemistry and Clinical Molecular Biology

Qualified Full Professor of Medical Oncology

Affiliation Università del Piemonte Orientale, Department of Health Sciences; via Paolo Solaroli 17 – 28100, Novara (Italy)

Website: <http://www.isidorolab.com/>
<https://upobook.uniupo.it/ciro.isidoro@med>

Education:

1983 – Laurea *Summa cum Laude* - Doctor in Biological Sciences (D.Sc.), Università di Torino (Italy)

1984 – National License for Board of Doctor Biologists

1999 - Laurea *Summa cum Laude* - Doctor in Medicine and Surgery (M.D.), Università del Piemonte Orientale (Novara, Italy)

2000 – National License for Board of Medical Doctors and Surgeons.

Representative Careers and affiliations:

2023: TOP 2% Scientist in the world based on scientific production in 2022.

1983-1986: post-lauream fellow at Università di Torino, Dipartimento di Medicina e Oncologia Sperimentale (Italy)

1986-1989: PhD fellow-Assistant Researcher (Rerum Medicinalis) at the Institut fuer Pathobiochemie, Westfaelish Wilhelms Universitaet Muenster (Germany); Wissenschaftliche Hilfskraft from 15.02.1989 through 31.03.1990.

1989-1992: Post-doc-Assistant Researcher at Università di Torino, Dipartimento di Medicina e Oncologia Sperimentale (Italy)

1993-1999: Assistant Professor of General Pathology, University of Turin (Italy)

2000 to 2019: Associate Professor of Cell Pathology and of Experimental Oncology, School of Medicine, Università del Piemonte Orientale (Novara, Italy).

2000-2000: Visiting Professor at Institute fuer Physiologische Chemie (Prof. A. Hasilik), Klinikum der Philipps-Universität Marburg (D)

2002-2005: Visiting Professor at Henry Wellcome Laboratories for Integrative Neuroscience and Endocrinology, University of Bristol (UK).

2005 to date: overseas advisor of PhD students at Mahidol University, at Chulalongkorn University, Bangkok; at Khon Kaen University (Thailand)

2013-2020: Visiting Professor, Siriraj Faculty of Medicine, Mahidol University of Bangkok (Thailand).

2016 to present: Visiting Professor, Department of Cell Biology, Oklahoma University Health Science Center (OKC, US).

2018 to 2019: Visiting Professor, Faculty of Allied Health Sciences, Chulalongkorn University of Bangkok (Thailand).

2019-2020: Visiting Professor, University of Bourgogne France-Comté, Besancon (France)

2019 to date: Full Professor of General Pathology, Cell Pathology and Experimental Oncology, School of Medicine, Università del Piemonte Orientale (Novara, Italy).

Biographical sketch CIRO ISIDORO

2019-2020 Adjunct Professor Dept of Medicine, College of Medicine, Seoul National University, Seoul (South Korea)

2019-2020: Adjunct Professor Medical Research Institute, Tokyo Medical and Dental University, Tokyo (Japan) 2020-

present: Adjunct Professor Siriraj Hospital-Faculty of Medicine, Mahidol University, Bangkok (Thailand)

Representative Awards:

2023: TOP 2% Best Scientists in the World among 8.5 million

2014: Professor Honoris Causa Faculty of Medicine and Pharmacy, Université de Bourgogne & Franche-Comté of Besançon (France).

2015: member of the Scientific board of « Integrative Cancer Research Center of the Georgia Institute of Technology », Georgia Tech University, Georgia (Atlanta, US) <https://icrc.gatech.edu/people/Ciro-Isidoro>; <https://icrc.gatech.edu/user/299>

2015: Executive Vice-President of the International Association of Traditional and Complementary Medicine.

2018: Full member of the World Academy of Sciences <http://www.worldacademyofsciences.com/members.html>

EDITORIAL BOARD

Editor-in-Chief of J Traditional and Complementary Medicine; of J of Molecular Signaling; J of Cancer and Metastasis Treatment; Biomedicines (Advisor board member)

Associate Editor of Autophagy, Cancers, Cells, Int J Molec Sci, Molecular Carcinogenesis, Frontiers in Oncology, Oncology Lett, Oncology Res, Exptl. & Therap. Medicine, (others)

Research Areas: Role and Regulation of Autophagy in Cancer and in Neurodegeneration. Epigenetic regulation of Autophagy and cell death. Anti-aging and anti-cancer Nutraceuticals. Organelle biogenesis, vesicular traffic, and diseases. Nanotheranostics ('in cellulo' imaging). Omics technology in human diseases diagnosis and therapy. Molecular and pathophysiological mechanisms of COVID-19 and of COVID19 vaccine's adverse effects.

International Patent (C. Follo e C. Isidoro), PCT No. WO2008/065505 (5-06-2008).

LINK: <https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2008065505&redirectedID=true>

Bibliometric index:

Scopus H Index = 46; citations >10.000

Google Scholar H Index = 50; citations >20.000

Google Scholar personal webpage <https://scholar.google.it/citations?hl=it&user=YaKkwGMAAAAJ>

Total Impact Factor >1000

Publications 182 full articles in peer-review journals plus chapters in several books.

PUBMED <https://www.ncbi.nlm.nih.gov/pubmed/?term=isidoro+c>

INTERNATIONAL SCIENTIFIC SOCIETY MEMBERSHIP

- International Society of Precision Cancer Medicine (founder member, since Apr 2018)
- International Association of Traditional and Complementary Medicine (Executive Vice President, since Nov 2015)
- International Proteolysis Society (founder member, since 1999)
- Associazione Italiana di Biologia Cellulare e del Differenziamento (ABCD) (founder member)
- Italian Society of Cancerology
- European Cancer Society
- European Cell Biology Society


TOP 2% Scientist in the world based on quality of scientific production in 2022.

Prof. Ciro Isidoro ranks 157259 among 8.5 million scientists in the world.

A bibliometric study performed by the Prof. J. Ioannidis's team at Stanford University has considered the quantity, quality, and diffusion of publications within the scientific community and elaborated standardized information on citations, h-index, co-authorship adjusted hm-index, citations to papers in different authorship positions and a composite indicator (c-score). The authors analyzed data relating to over 8 and a half million researchers from universities and research centers throughout the world. Among them, approximately **195,000 scientists stood out for their scientific authority and currently represent the best 2%. In this ranking, Prof. Ciro Isidoro is n. 157259.**

<https://elsevier.digitalcommonsdata.com/datasets/btchxktzyw/6>

https://drive.google.com/file/d/1ro19angG6WqVA5zX9vUISegw38QLQok0/view?usp=drive_web




<https://exaly.com/author/5026208/ciro-isidoro/h-index>

Best Biology and Biochemistry Scientists

The 2nd edition of Research.com ranking of the best scientists in the field of Biology and Biochemistry relies on data derived from a wide range of data sources including OpenAlex and CrossRef. The bibliometric data for devising the citation-based metrics were acquired on 21-12-2022. Position in the ranking is based on a scholar's D-index (Discipline H-index), which takes into account only publications and citation values for an examined discipline.

[Show more](#)

World	National	Scholar	D-Index	Citations	Publications
12866	386	 Ciro Isidoro University of Eastern Piedmont Amadeo Avogadro, Italy	50	32,485	170

The 2023 Edition of our Ranking of Top Scientists in the field of Biology and Biochemistry released recently at

<https://research.com/scientists-rankings/biology-and-biochemistry>

Biographical sketch CIRO ISIDORO

TOP ITALIAN SCIENTIST IN BIOMEDICAL SCIENCES

<https://topitalianscientists.org/top-italian-scientists-scopus/Biomedical%20Sciences/1>

Top Italian Scientists							
Biomedical Sciences							
Sciences							
1329	Ciro Isidoro	48	19,885	Italy	cancer - medicine	Biomedical Sciences	Università degli Studi del Piemonte Orientale "Amedeo Avogadro"

CODICE FISCALE SDRCRI56M29Z326U;

"Ai sensi del GDPR (2016/679) e della normativa vigente in materia di privacy autorizzo il trattamento dei miei dati personali. Dichiaro, inoltre, che ogni informazione espressa nel presente Curriculum Vitae corrisponde a verità".

Autorizzo e consento il trattamento dei miei dati personali ai sensi dell'art. 13 del D.Lgs. 196/03 e dell'art. 13 GDPR 679/16 e Decreto Legislativo 30 giugno 2003, n. 196 "Codice in materia di protezione dei dati personali".

Novara, April 16th, 2024

Biographical sketch CIRO ISIDORO

MOST RECENT SELECTED PUBLICATIONS (2024)

182. Secomandi, E.; Esposito, A.; Camurani, G.; Vidoni, C.; Salwa, A.; Lualdi, C.; Vallino, L.; Ferraresi, A.; Isidoro, C. Differential Competitive Growth of Transgenic Subclones of Neuroblastoma Cells Expressing Different Levels of Cathepsin D Co-Cultured in 2D and 3D in Response to EGF: Implications in Tumor Heterogeneity and Metastasis. *Cancers* **2024**, *16*, 1343. <https://doi.org/10.3390/cancers16071343>
181. Sillapachaiyaporn C, Wongwan C, Mongkolpobsin K, Nilkhet S, Isidoro C, Chuchawankul S, Tencomnao T. Ergosterol promotes neurite outgrowth, inhibits amyloid-beta synthesis, and extends longevity: In vitro neuroblastoma and in vivo *Caenorhabditis elegans* evidence. *Life Sci.* 2024 Apr 2:122606. doi: 10.1016/j.lfs.2024.122606. Epub ahead of print. PMID: 38574884.
180. Ferraresi A, Thongchot S, Isidoro C. Resveratrol Promotes Self-digestion to Put Cancer to Sleep. *J Cancer Prev.* 2024 Mar 30;29(1):1-5. doi: 10.15430/JCP.24.001. Epub 2024 Mar 29. PMID: 38567110; PMCID: PMC10982519.
179. Chen X, Tsvetkov AS, Shen HM, Isidoro C, Ktistakis NT, Linkermann A, Koopman WJH, Simon HU, Galluzzi L, Luo S, Xu D, Gu W, Peulen O, Cai Q, Rubinsztein DC, Chi JT, Zhang DD, Li C, Toyokuni S, Liu J, Roh JL, Dai E, Juhasz G, Liu W, Zhang J, Yang M, Liu J, Zhu LQ, Zou W, Piacentini M, Ding WX, Yue Z, Xie Y, Petersen M, Gewirtz DA, Mandell MA, Chu CT, Sinha D, Eftekharpour E, Zhivotovsky B, Besteiro S, Gabrilovich DI, Kim DH, Kagan VE, Bayir H, Chen GC, Ayton S, Lünemann JD, Komatsu M, Krautwald S, Loos B, Baehrecke EH, Wang J, Lane JD, Sadoshima J, Yang WS, Gao M, Münz C, Thumm M, Kampmann M, Yu D, Lipinski MM, Jones JW, Jiang X, Zeh HJ, Kang R, Klionsky DJ, Kroemer G, Tang D. International consensus guidelines for the definition, detection, and interpretation of autophagy-dependent ferroptosis. *Autophagy.* 2024 Mar 5. doi: 10.1080/15548627.2024.2319901. Epub ahead of print. PMID: 38442890.
178. Thongchot S, Ferraresi A, Vidoni C, Salwa A, Vallino L, Kittirat Y, Loilome W, Namwat N, Isidoro C. Preclinical evidence for preventive and curative effects of resveratrol on xenograft cholangiocarcinogenesis. *Cancer Lett.* 2023 Dec 12:216589. doi: 10.1016/j.canlet.2023.216589. Epub ahead of print. PMID: 38097133.
177. Fawaz A, Ferraresi A, Isidoro C. Systems Biology in Cancer Diagnosis Integrating Omics Technologies and Artificial Intelligence to Support Physician Decision Making. *J Pers Med.* 2023 Nov 10;13(11):1590. doi: 10.3390/jpm13111590. PMID: 38003905.
176. Nadhan, R., Isidoro, C., Song, Y.S., Dhanasekaran, D.N. (2023). Long Non-coding RNAs in Cancer. In: Sobti, R.C., Ganguly, N.K., Kumar, R. (eds) *Handbook of Oncobiology: From Basic to Clinical Sciences*. Springer, Singapore. https://doi.org/10.1007/978-981-99-2196-6_37-1
175. Amreen Salwa, Alessandra Ferraresi, Eleonora Secomandi, Letizia Vallino, Riccardo Moia, Andrea Patriarca, Beatrice Garavaglia, Gianluca Gaidano, Ciro Isidoro. High BECN1 Expression Negatively Correlates with BCL2 Expression and Predicts Better Prognosis in Diffuse Large B-Cell Lymphoma: Role of Autophagy. *Cells* **2023**, *12*(15), 1924; <https://doi.org/10.3390/cells12151924>
174. Isidoro C. Pathophysiology of Lysosomes in a Nutshell. *Int J Mol Sci.* 2023 Jun 26;24(13):10688. doi: 10.3390/ijms241310688. PMID: 37445864
173. Editorial: Metabolome in gastrointestinal cancer. Isidoro C, Teng Y. *Front Oncol.* 2023 Jun 26;13:1234242. doi: 10.3389/fonc.2023.1234242. eCollection 2023. PMID: 37434972
172. Nadhan R, Kashyap S, Ha JH, Jayaraman M, Song YS, Isidoro C, Dhanasekaran DN. Targeting Oncometabolites in Peritoneal Cancers: Preclinical Insights and Therapeutic Strategies. *Metabolites* **2023**, *13*(5), 618; <https://doi.org/10.3390/metabo13050618>

Biographical sketch CIRO ISIDORO

171. Vallino L, Garavaglia B, Visciglia A, Amoruso A, Pane M, Ferraresi A, Isidoro C. Cell-free Lactiplantibacillus plantarum OC01 supernatant suppresses IL-6-induced proliferation and invasion of human colorectal cancer cells: Effect on β -Catenin degradation. *J Tradit Complement Med.* 2023 Feb 21;13(2):193-206. doi: 10.1016/j.jtcme.2023.02.001. eCollection 2023
170. Editorial note: Gut microbiota and health. Ho CT, Wu MS, Panyod S, Chang AC, Isidoro C, Sheen LY. *J Tradit Complement Med.* 2023 Mar 13;13(2):105-106. doi: 10.1016/j.jtcme.2023.03.004. eCollection 2023
169. Rubio K, Hernández-Cruz EY, Rogel-Ayala DG, Sarvari P, Isidoro C, Barreto G, Pedraza-Chaverri J. Nutriepigenomics in Environmental-Associated Oxidative Stress. *Antioxidants (Basel).* 2023 Mar 21;12(3):771. doi: 10.3390/antiox12030771.
168. Paolo Bellavite, Alessandra Ferraresi, Ciro Isidoro. Immune response and molecular mechanisms of cardiovascular adverse effects of Spike proteins from SARS-CoV-2 and mRNA vaccines. *Biomedicines* 2023, 11(2), 451; <https://doi.org/10.3390/biomedicines11020451>
167. Chiara Vidoni, Alessandra Ferraresi, Letizia Vallino, Amreen Salwa, Ji Hee Ha, Christian Seca, Beatrice Garavaglia, Danny N. Dhanasekaran, Ciro Isidoro Glycolysis Inhibition of Autophagy Drives Malignancy in Ovarian Cancer: Exacerbation by IL-6 and Attenuation by Resveratrol. *Int. J. Mol. Sci.* 2023, 24(2), 1723; <https://doi.org/10.3390/ijms24021723> (<https://www.mdpi.com/1422-0067/24/2/1723>)
166. Ferraresi A., Isidoro C. Will Omics Biotechnologies Save Us from Future Pandemics? Lessons from COVID-19 for Vaccinomics and Adversomics. *Biomedicines* 2023, 11(1), 52; <https://doi.org/10.3390/biomedicines11010052>.